7,945 followers
A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma. https://t.co/Pz2N9i5u8s
A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.
Overview of attention for article published in Journal of Clinical Oncology, May 2021
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (86th percentile)
-
Good Attention Score compared to outputs of the same age and source (68th percentile)
Readers on
- mendeley
- 13 Mendeley